HIV 诊断市场 - 全球产业规模、份额、趋势、机会和预测，按产品、按检测类型（抗体检测、病毒载量检测、CD4 检测等）、按模式、按最终用途、按地区和竞争情况细分，2020 年至 2030 年

2024 年全球 HIV 诊断市场价值为 45.3 亿美元，预计到 2030 年将达到 74.7 亿美元，年复合成长率(CAGR) 为 8.68%。自 20 世纪 80 年代初爱滋病出现以来，爱滋病毒诊断领域发生了重大变化。诊断技术的进步、公众意识的提高以及更广泛的检测机会在全球应对爱滋病毒/爱滋病疫情中发挥了关键作用。如今，爱滋病毒诊断领域是一个充满活力且快速发展的行业，为改善疾病管理并最终根除疾病带来了新的希望。

HIV（人类免疫缺乏病毒）透过攻击对于抵抗感染至关重要的 CD4 细胞来损害免疫系统。如果不及时治疗，爱滋病毒会发展为爱滋病（后天免疫缺乏症候群），增加机会性感染和某些癌症的可能性。儘管不断做出努力，全球爱滋病毒/爱滋病疫情仍然是一个紧迫的公共卫生问题，全世界数百万人受到影响。根据联合国爱滋病规划署统计，截至 2019 年，全球约有 3,800 万人感染爱滋病毒。虽然在降低感染率和爱滋病相关死亡率方面取得了进展，但持续存在的挑战凸显了可近性、准确的诊断方法对于减轻病毒影响的重要性。

市场驱动因素

爱滋病毒感染率上升推动诊断需求

市场挑战

无障碍和认知障碍

市场趋势

技术创新推动市场扩张

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球爱滋病毒诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按产品（耗材、仪器、软体和服务）
  • 依检测类型（抗体检测（HIV-1 筛检检测、HIV-1 抗体确认检测、HIV-2 和 O 组诊断检测）、病毒量检测、CD4 检测、其他）
  • 按模式（自测、基于实验室）
  • 依最终用途（诊断实验室、医院和诊所、家庭环境）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美HIV诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲HIV诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区爱滋病毒诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲爱滋病毒诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲爱滋病毒诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Thermo Fisher Scientific, Inc.
• Alere Inc.
• Abbott Laboratories inc.
• Bristol-Myers Squibb Company
• Janssen Global Services, LLC
• Gilead Sciences, Inc.
• Merck & Co. Inc.
• VIIV Healthcare
• Beckman Coulter, Inc.
• Sysmex Europe SE
• Zyomtronix, Inc.
• Mylan NV
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare GmbH

第 15 章：策略建议

第16章调查会社について・免责事项

Global HIV Diagnostics market was valued at USD 4.53 billion in 2024 and is projected to reach USD 7.47 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.68%. Since the emergence of AIDS in the early 1980s, the HIV diagnostics landscape has evolved significantly. Advances in diagnostic technologies, increased public awareness, and broader access to testing have all played pivotal roles in the global response to the HIV/AIDS epidemic. Today, the HIV diagnostics sector represents a dynamic and rapidly advancing industry, offering renewed hope for improved disease management and, ultimately, eradication.

HIV (Human Immunodeficiency Virus) compromises the immune system by targeting CD4 cells, critical to defending against infections. Without timely treatment, HIV can progress to AIDS (Acquired Immunodeficiency Syndrome), increasing vulnerability to opportunistic infections and certain cancers. Despite ongoing efforts, the global HIV/AIDS epidemic remains a pressing public health concern, with millions affected worldwide. According to UNAIDS, approximately 38 million individuals were living with HIV as of 2019. While progress has been made in reducing infection rates and AIDS-related mortality, persistent challenges underscore the importance of accessible, accurate diagnostics in mitigating the virus's impact.

Market Drivers

Rising HIV Prevalence Fueling Demand for Diagnostics

The growing global prevalence of HIV/AIDS continues to be a major driver of the HIV diagnostics market. As per the World Health Organization (WHO), around 39.9 million people were living with HIV at the end of 2023, with Sub-Saharan Africa remaining the most affected region, accounting for over two-thirds of global cases. However, HIV continues to affect populations worldwide, reinforcing the universal demand for reliable diagnostic solutions.

Despite preventive measures and treatment advancements, the incidence of new HIV infections remains concerning. In 2023 alone, an estimated 1.3 million individuals acquired HIV. Contributing factors include limited access to preventive education, lack of contraceptive availability, and ongoing social stigma, which impedes testing and treatment efforts. The growing global population also means a rise in the absolute number of individuals living with HIV, thereby intensifying the need for early detection and clinical management.

Timely diagnosis is essential for initiating antiretroviral therapy (ART), which improves quality of life and reduces the risk of transmission. Early detection also helps prevent disease progression to AIDS, subsequently lowering mortality rates. In 2023, AIDS-related illnesses claimed approximately 630,000 lives worldwide. As such, the increasing burden of HIV has bolstered the demand for robust diagnostic tools, reinforcing their role in treatment planning, prevention, and public health management.

Market Challenges

Barriers to Accessibility and Awareness

Despite advancements, significant challenges persist, particularly in low- and middle-income countries where healthcare systems often lack the resources necessary for effective HIV diagnosis. In many rural and underserved areas, diagnostic services are limited due to poor infrastructure, inadequate transportation, and a shortage of trained medical personnel. These systemic gaps lead to late diagnoses and delayed treatment initiation.

Even in areas where diagnostic tools are available, factors such as inconsistent electricity supply, inadequate refrigeration for test kits, and substandard sanitary conditions compromise test accuracy. Moreover, social stigma, fear of discrimination, and misinformation continue to deter individuals from seeking testing. Misperceptions about personal risk and reluctance to discuss sexual health further hinder diagnosis efforts. In regions where comprehensive sex education is lacking, knowledge gaps contribute to the continued spread of HIV.

Cultural and language barriers, as well as insufficiently localized public health campaigns, further limit the effectiveness of outreach programs. Bridging these gaps requires a multifaceted strategy, including investment in healthcare infrastructure, community-based awareness initiatives, and integration of HIV testing into routine healthcare services. Closing the accessibility and awareness gap is crucial for improving early detection and reducing global HIV transmission rates.

Market Trends

Technological Innovation Driving Market Expansion

The HIV diagnostics market has been notably influenced by continuous advancements in testing technologies. One of the most transformative developments has been the rise of point-of-care testing (POCT) devices. These portable tools deliver rapid results-often within 30 minutes-enabling immediate clinical action and reducing transmission risks. POCT has been particularly valuable in resource-constrained environments lacking advanced laboratory infrastructure.

Nucleic acid testing (NAT) has further enhanced diagnostic accuracy by detecting the virus's genetic material directly, allowing for earlier identification and minimizing false-negative results. In parallel, next-generation sequencing (NGS) technologies have facilitated deeper understanding of HIV strain diversity, which is vital given the virus's high mutation rate. This knowledge supports the development of more targeted diagnostics and therapies.

Modern serological assays, such as chemiluminescence immunoassays and multiplex bead-based platforms, offer improved sensitivity and specificity. These tests can differentiate between HIV-1 and HIV-2 and are less susceptible to false positives.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Alere Inc.
• Abbott Laboratories inc.
• Bristol-Myers Squibb Company
• Janssen Global Services, LLC
• Gilead Sciences, Inc.
• Merck & Co. Inc.
• VIIV Healthcare
• Beckman Coulter, Inc.
• Sysmex Europe SE
• Zyomtronix, Inc.
• Mylan N.V.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare GmbH

Report Scope:

In this report, the Global HIV Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HIV Diagnostics Market, By Product:

• Consumables
• Instruments
• Software and Services

HIV Diagnostics Market, By Test Type:

• Antibody Tests
• Viral Load Tests
• CD4 Test
• Others

HIV Diagnostics Market, By Mode:

• Self-Test
• Lab-based

HIV Diagnostics Market, By End-use:

• Diagnostic Laboratories
• Hospitals & Clinics
• Home Settings

HIV Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HIV Diagnostics Market.

Available Customizations:

Global HIV Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global HIV Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables, Instruments, Software and Services)
  • 5.2.2. By Test Type (Antibody Tests(HIV-1 Screening Tests, HIV-1 Antibody Confirmatory Tests, HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Test, Others)
  • 5.2.3. By Mode (Self-Test, Lab-based)
  • 5.2.4. By End-use (Diagnostic Laboratories, Hospitals & Clinics, Home Settings)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America HIV Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Test Type
  • 6.2.3. By Mode
  • 6.2.4. By End-use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States HIV Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By Mode
      • 6.3.1.2.4. By End-use
  • 6.3.2. Mexico HIV Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By Mode
      • 6.3.2.2.4. By End-use
  • 6.3.3. Canada HIV Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By Mode
      • 6.3.3.2.4. By End-use

7. Europe HIV Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Test Type
  • 7.2.3. By Mode
  • 7.2.4. By End-use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France HIV Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By Mode
      • 7.3.1.2.4. By End-use
  • 7.3.2. Germany HIV Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By Mode
      • 7.3.2.2.4. By End-use
  • 7.3.3. United Kingdom HIV Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By Mode
      • 7.3.3.2.4. By End-use
  • 7.3.4. Italy HIV Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By Mode
      • 7.3.4.2.4. By End-use
  • 7.3.5. Spain HIV Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By Mode
      • 7.3.5.2.4. By End-use

8. Asia-Pacific HIV Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Test Type
  • 8.2.3. By Mode
  • 8.2.4. By End-use
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China HIV Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By Mode
      • 8.3.1.2.4. By End-use
  • 8.3.2. India HIV Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By Mode
      • 8.3.2.2.4. By End-use
  • 8.3.3. South Korea HIV Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By Mode
      • 8.3.3.2.4. By End-use
  • 8.3.4. Japan HIV Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Test Type
      • 8.3.4.2.3. By Mode
      • 8.3.4.2.4. By End-use
  • 8.3.5. Australia HIV Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Test Type
      • 8.3.5.2.3. By Mode
      • 8.3.5.2.4. By End-use

9. South America HIV Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Test Type
  • 9.2.3. By Mode
  • 9.2.4. By End-use
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil HIV Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By Mode
      • 9.3.1.2.4. By End-use
  • 9.3.2. Argentina HIV Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By Mode
      • 9.3.2.2.4. By End-use
  • 9.3.3. Colombia HIV Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By Mode
      • 9.3.3.2.4. By End-use

10. Middle East and Africa HIV Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Test Type
  • 10.2.3. By Mode
  • 10.2.4. By End-use
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa HIV Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By Mode
      • 10.3.1.2.4. By End-use
  • 10.3.2. Saudi Arabia HIV Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By Mode
      • 10.3.2.2.4. By End-use
  • 10.3.3. UAE HIV Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By Mode
      • 10.3.3.2.4. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Thermo Fisher Scientific, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Alere Inc.
• 14.3. Abbott Laboratories inc.
• 14.4. Bristol-Myers Squibb Company
• 14.5. Janssen Global Services, LLC
• 14.6. Gilead Sciences, Inc.
• 14.7. Merck & Co. Inc.
• 14.8. VIIV Healthcare
• 14.9. Beckman Coulter, Inc.
• 14.10. Sysmex Europe SE
• 14.11. Zyomtronix, Inc.
• 14.12. Mylan N.V.
• 14.13. F. Hoffmann-La Roche Ltd.
• 14.14. Siemens Healthcare GmbH

15. Strategic Recommendations

16. About Us & Disclaimer